Stockreport

Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study

Axon Enterprise, Inc.  (AXON) 
Last axon enterprise, inc. earnings: 2/7 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF -- Intepirdine Program to be Discontinued Based on MINDSET, HEADWAY, and Gait and Balance Study Results ---- Company to Advance to Larger Confirmatory Nelotanserin DLB S [Read more]